Irene Fusi

Irene Fusi

Auto-generated profile, based on publicly available information

Irene Fusi

Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
IFIrene Fusi
Irene Fusi
CSClara Serger
Clara Serger
PHPetra Herzig
Petra Herzig
MGMarkus Germann
Markus Germann
MSMichael T. Sandholzer
Michael T. Sandholzer
AZAlfred Zippelius
Alfred Zippelius
Antibody-cytokine fusion proteins are being developed as next-generation cancer immunotherapies, aiming to deliver activation signals to targeted immune populations. Among these, PD1-IL2v—an engineered interleukin-2 variant (IL-2v) lacking CD25 binding, fused to a high-affinity programmed cell death protein 1 (PD-1) blocking antibody—has shown promising results in murine tumor models. Here, using human model systems, we show that PD1-IL2v elicits a multifaceted antitumor T cell response by targeting both CD8 + and conventional CD4 + T (T conv ) cells. Single-cell RNA sequencing (scRNAseq) on a lung cancer patient–derived tumor fragment (PDTF) platform revealed that PD1-IL2v drives the expansion of proliferative, cytotoxic CD8 + T cells exhibiting features of tumor reactivity. This was accompanied by up-regulation of CXCR6, enhancing their migratory capacity. In T conv cells, PD1-IL2v up-regulated CXCL13 expression and promoted a T follicular helper/T helper 1 (T FH /T H 1)–like transcriptional program associated with anti-PD1 responsiveness. Our findings provide mechanistic insights into the effects of IL-2v–targeted delivery to PD-1 + cells within human tumors, supporting the clinical development of next-generation immunocytokines.

5 June 2026 in Science Immunology
Verified
Journal Article
Closed access
CSClara Serger
Clara Serger
LRLucas Rebuffet
Lucas Rebuffet
MSMichael T. Sandholzer
Michael T. Sandholzer
WRWiebke Rackwitz
Wiebke Rackwitz
IFIrene Fusi
Irene Fusi
AZAlfred Zippelius
Alfred Zippelius
Natural killer (NK) cell–targeting immunotherapies are emerging, yet the differentiation and functional states of tumor-infiltrating NK cells remain poorly understood. Using matched single-nucleus RNA and ATAC sequencing of samples from patients with non–small cell lung cancer (NSCLC), we resolved the transcriptional and epigenetic landscape of intratumoral NK cells. We identified two tumor-associated NK (taNK) cell subsets marked by expression of ITGAE (CD103) and ITGA1 (CD49a) that display features of tissue residency and dysfunction while preserving cytotoxic function. Trajectory and regulon analyses revealed an inflammation-driven transition from early granzyme K ( GZMK ) + NK cells toward an ENTPD1 + (CD39 + ) effector state characterized by interferon-stimulated gene (ISG) programs. Functional profiling established CD39 + taNK cells as the dominant cytotoxic NK cell population with superior killing capacity that was further potentiated by NKG2A blockade. This study offers mechanistic insights into NK cell differentiation in NSCLC and establishes CD39 + taNK cells as a targetable effector population for immunotherapy.